TORONTO, Ontario — January 19, 2026 — Leads & Copy — David Pidduck will step down as CEO of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) effective Jan. 23, 2026. The Board of Directors has appointed Greg Hunter, current CFO, as Interim CEO while evaluating long-term leadership plans. Hunter will continue to serve as CFO during the interim period.
Pidduck played a critical role in stabilizing and repositioning MediPharm, executing restructuring initiatives, improving profitability, and integrating VIVO Cannabis Inc. after its acquisition in April 2023. He will remain on the Board to ensure a seamless transition.
Hunter assumed the CFO role in February 2021 and has implemented cost-reduction initiatives, strengthened financial controls, and been involved in commercial strategy, working with sales, marketing, and product teams to enhance pricing, support customer programs, negotiate commercial terms, and align manufacturing with market demand.
Hunter brings over 20 years of cross-functional leadership experience from Fortune 500 organizations, including Johnson & Johnson and Baxter, as well as private equity portfolio companies. His experience spans finance, sales, marketing, and operations.
Board Chair Chris Taves thanked Pidduck for his contributions, noting his role in strengthening MediPharm’s financial trajectory during challenging market conditions. Taves also expressed confidence in Hunter’s ability to drive execution, operational discipline, and growth.
MediPharm Labs, founded in 2015, specializes in purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. The company has invested in research, technology, purification methodologies, and facilities to deliver cannabinoid products for domestic and international markets.
In 2021, MediPharm received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale, domestic GMP license for the extraction of multiple natural cannabinoids. In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to Canadian medical patients through the Canna Farms e-commerce platform, and internationally through Beacon Medical operations in Australia and Germany. The acquisition also added Harvest Medical Clinics in Canada.
MediPharm operates in compliance with all applicable laws.
Contact: MediPharm Labs Investor Relations, 1 416.913.7425, investors@medipharmlabs.com
Source: MediPharm Labs Corp.
